<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02176863</url>
  </required_header>
  <id_info>
    <org_study_id>IG1104</org_study_id>
    <nct_id>NCT02176863</nct_id>
  </id_info>
  <brief_title>Study of the Efficacy and Safety of Immune Globulin Intravenous (Human) Flebogamma® 5% DIF in Patients With Post-polio Syndrome</brief_title>
  <acronym>FORCE</acronym>
  <official_title>A Multicenter, Prospective, Randomized, Placebo-controlled, Double-blind, Parallel‑Group Clinical Trial to Assess the Efficacy and Safety of Immune Globulin Intravenous (Human) Flebogamma® 5% DIF in Patients With Post-Polio Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Instituto Grifols, S.A.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Grifols Biologicals Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicenter, prospective, randomized, placebo-controlled, double-blind, parallel
      group clinical trial with adaptive dose selection in subjects with post polio syndrome (PPS).

      The main purpose of this study is to select a dose of Flebogamma 5% DIF and confirm the
      efficacy of the selected Flebogamma 5% DIF dose by assessing physical performance, as
      measured by 2 Minutes Walk Distance (2MWD) test.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a phase II/III multicentre, prospective, randomized, placebo-controlled,
      double-blind, parallel‑group clinical trial with an adaptive design (flexible group
      sequential design with adaptive dose selection) in subjects with PPS.

      This study will consist of two stages. The first stage (Stage 1) is for dose selection, and
      the second stage (Stage 2) is to establish the superiority (efficacy confirmation) of
      Flebogamma® 5% DIF and for overall safety analysis. At Stage 1, three treatment arms,
      Flebogamma® 5% DIF 2 g/kg of body weight (IVIG 2 g/kg arm), or the equivalent volume of
      Normal Saline Solution (40 ml/kg of body weight), or Flebogamma® 5% DIF 1 g/kg of body weight
      plus the equivalent volume of Normal Saline Solution (20 ml/kg of body weight) (IVIG 1 g/kg
      arm) will be administered every 4 weeks over two consecutive days during a 52-week treatment
      period. At Stage 2, two treatment arms, the selected dose of Flebogamma® 5% DIF from Stage 1
      and Normal Saline Solution (40 ml/kg of body weight), will be administered every 4 weeks over
      two consecutive days during a 52-week treatment period. During Stage 2, the selected dose of
      Flebogamma® 5% DIF and Normal Saline Solution will be administered in the same manner as in
      Stage 1, including administering the total dose for both treatment arms at a volume
      equivalent to that for the IVIG 2 g/kg arm, regardless of the selected dose.

      Primary efficacy endpoint will be:

        -  Physical performance (2MWD) from baseline to the end of the treatment period (at End of
           Treatment Visit -Week 52).

      Secondary efficacy endpoints will be:

        -  Pain (VAS of pain) from baseline to the end of the treatment period.

        -  HRQoL (SF-36 PCS) from baseline to the end of the treatment period.

        -  Endurance (6MWD) from baseline to the end of the treatment period.

      Exploratory endpoints will be:

        -  Muscle strength of at least two newly weakened muscle groups (Manual Muscle Testing
           [MMT] using the modified Medical Research Council [MRC] scale) from baseline to the end
           of the treatment period.

        -  Muscle strength of at least two newly weakened muscle groups (Quantitative Muscle
           Testing [QMT] using a dynamometer) from baseline to the end of the treatment period.

        -  Walking activity in daily life (pedometer) from baseline to the end of the treatment
           period.

        -  Subject's self-perceived exertion/fatigue level using the Borg scale before and after
           the 2MWD and 6MWD from baseline to the end of the treatment period.

        -  Fatigue (Fatigue Severity Scale [FSS]) from baseline to the end of the treatment period.

        -  HRQoL (SF-36 Mental Component Summary [MCS]) from baseline to the end of the treatment
           period.

        -  Blood and CSF (CSF is optional) inflammatory cytokines (IL-1, IL-4, IL-6, IL-10, IL-13,
           IL-17, IL-23, TNF-alpha, and IFN-gamma) from baseline to the end of the treatment
           period.

        -  Sustained effect of Flebogamma® 5% DIF compared to placebo as measured by:

             1. Physical performance (2MWD) from baseline to Followup Visit (FU) (Week 64) and to
                the Final Visit (FV; Week 76).

             2. Pain (VAS of pain) from baseline to FU3 and to the FV.

             3. HRQoL (SF-36 PCS) from baseline to FU3 and to the FV.

             4. Endurance (6MWD) from baseline to FU3 and to the FV.

             5. Muscle strength (MMT using the MRC scale) from baseline to the FV.

             6. Muscle strength (QMT using a dynamometer) from baseline to the FV.

             7. Walking activity in daily life (pedometer) from baseline to the FV.

             8. Fatigue (FSS) from baseline to the FV.

             9. HRQoL (SF-36 MCS) from baseline to FU3 and to the FV.

            10. Blood and CSF (CSF is optional) inflammatory cytokines from baseline to the FV.

      Safety endpoints will include Adverse Events (AEs), vital signs during infusions, physical
      assessments and blood tests for clinical safety.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 23, 2014</start_date>
  <completion_date type="Anticipated">June 2021</completion_date>
  <primary_completion_date type="Anticipated">January 2021</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in 2MWD</measure>
    <time_frame>Baseline, Week 52</time_frame>
    <description>Physical performance (2MWD) from baseline (at Enrollment Visit) to the end of the treatment period</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Visual Analogue Scale (VAS) of pain</measure>
    <time_frame>Baseline, Week 52</time_frame>
    <description>Pain (Visual Analogue Scale [VAS] of pain) from baseline to the end of the treatment period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Medical Outcomes Study 36-Item Short Form Health Survey (SF-36) Physical Component Summary (PCS)</measure>
    <time_frame>Baseline, Week 52</time_frame>
    <description>HRQoL (Medical Outcomes Study 36-Item Short Form Health Survey [SF-36] Physical Component Summary</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Six Minutes Walk Distance (6MWD)</measure>
    <time_frame>Baseline, Week 52</time_frame>
    <description>Endurance (Six-Minute Walk Distance [6MWD]) from baseline to the end of the treatment period.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Muscle Strength of two newly weakened muscle groups (MMT using the MRC scale)</measure>
    <time_frame>Baseline, Week 52</time_frame>
    <description>Muscle strength of 2 newly weakened muscle groups (Manual Muscle Testing [MMT] using the Medical Research Council [MRC] scale) from baseline to the end of the treatment period.</description>
  </other_outcome>
  <other_outcome>
    <measure>Muscle strength of two newly weakened muscle groups (QMT using a dynamometer)</measure>
    <time_frame>Baseline, Week 52</time_frame>
    <description>Muscle strength of 2 newly weakened muscle groups (Quantitative Muscle Testing [QMT] using a dynamometer) from baseline to the end of the treatment period.</description>
  </other_outcome>
  <other_outcome>
    <measure>Walking activity in daily life (pedometer)</measure>
    <time_frame>Baseline, Week 52</time_frame>
    <description>Walking activity in daily life (pedometer)</description>
  </other_outcome>
  <other_outcome>
    <measure>Subject's self-perceived exertion/fatigue level using the Borg scale</measure>
    <time_frame>Baseline, Week 52</time_frame>
    <description>Subject's self-perceived exertion/fatigue level using the Borg scale</description>
  </other_outcome>
  <other_outcome>
    <measure>Fatigue (FSS)</measure>
    <time_frame>Baseline, Week 52</time_frame>
    <description>Fatigue (FSS)</description>
  </other_outcome>
  <other_outcome>
    <measure>HRQoL (SF-36 MCS)</measure>
    <time_frame>Baseline, Week 52</time_frame>
    <description>HRQoL (SF-36 MCS)</description>
  </other_outcome>
  <other_outcome>
    <measure>Blood and CSF (CSF is optional) inflammatory cytokines</measure>
    <time_frame>Baseline, Week 52</time_frame>
    <description>Blood and CSF (CSF is optional) inflammatory cytokines</description>
  </other_outcome>
  <other_outcome>
    <measure>Sustained effect of Flebogamma 5% DIF compared to placebo</measure>
    <time_frame>Baseline, Week 76</time_frame>
    <description>Sustained effect of Flebogamma® 5% DIF compared to placebo as measured by:
Physical performance (2MWD) from baseline to FU3 (Week 64) and to the FV (Week 76).
Pain (VAS of pain) from baseline to FU3 and to the FV.
HRQoL (SF-36 PCS) from baseline to FU3 and to the FV.
Endurance (6MWD) from baseline to FU3 and to the FV
Muscle strength (MMT using the MRC scale) from baseline to the FV.
Muscle strength (QMT using a dynamometer) from baseline to the FV.
Walking activity in daily life (pedometer) from baseline to the FV.
Fatigue (FSS) from baseline to the FV.
HRQoL (SF-36 MCS) from baseline to FU3 and to the FV.
Blood and CSF (CSF is optional) inflammatory cytokines from baseline to the FV.</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">210</enrollment>
  <condition>Post-polio Syndrome</condition>
  <arm_group>
    <arm_group_label>2 g/kg Flebogamma 5% DIF</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Flebogamma 5% DIF, 2 g/kg, intravenous infusion every 4 weeks over two days for 52 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>1 g/kg Flebogamma 5% DIF</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Flebogamma 5% DIF, 1 g/kg, intravenous infusion every 4 weeks over two days for 52 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Normal Saline Solution, matching volume, intravenous infusion every 4 weeks over two days for 52 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Flebogamma 5% DIF</intervention_name>
    <description>Human plasma-derived immunoglobulin</description>
    <arm_group_label>2 g/kg Flebogamma 5% DIF</arm_group_label>
    <arm_group_label>1 g/kg Flebogamma 5% DIF</arm_group_label>
    <other_name>immune globulin intravenous (human)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Normal saline solution</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  BMI less than 35 kg/m2.

          -  March-of-Dimes clinical criteria for diagnosis of PPS.

          -  Ambulatory or are able to walk with a cane or other aids or use a wheelchair (but they
             are not wheelchair-bound).

          -  Subjects who have at least 2 newly weakened muscle groups due to PPS (as defined by
             medical history), with at least 1 of them in a lower extremity, and having an MRC
             scale score greater than 3 at the MMT performed by the independent assessor at the SV.

          -  Female of child-bearing potential must have a negative test for pregnancy.

          -  Female of child-bearing potential and their sexual partners have agreed to practice
             contraception using a method of proven reliability.

          -  Able to walk a 2MWD of at least 50 meters.

          -  Subjects who are able to walk a consistent baseline 2 MWD, that is, the difference in
             2MWD between the SV and EV/IV1 is not more than 10%.

        Exclusion Criteria:

          -  Have received human normal immune globulin treatment given by intravenous,
             subcutaneous or intramuscular route within the last 3 years.

          -  Are not ambulatory (wheelchair-bound individuals).

          -  Poor venous access.

          -  Intractable pain requiring narcotics or other psychotropic drugs.

          -  History of anaphylactic reactions or severe reactions to any blood-derived product.

          -  History of intolerance to any component of the investigational products, such as
             sorbitol.

          -  Receiving corticosteroids, except for those for asthma.

          -  Documented diagnosis of hyperviscosity or hypercoagulable state or thrombotic
             complications to polyclonal IVIG therapy in the past.

          -  History of recent (within the last year) myocardial infarction, stroke, or
             uncontrolled hypertension.

          -  Suffer from congestive heart failure, embolism, or electrocardiogram changes
             indicative of unstable angina or atrial fibrillation.

          -  History of chronic alcoholism or illicit drug abuse (addiction) in the preceding 12
             months.

          -  Active psychiatric illness that interferes with compliance or communication with
             health care personnel.

          -  Depression with scores &gt;30 as assessed by the Center for Epidemiologic Studies
             Depression validated scale.

          -  Females who are pregnant or are nursing an infant child.

          -  Currently receiving, or have received within 3 months prior to the Screening Visit,
             any investigational medicinal product or device.

          -  Known selective IgA deficiency and serum antibodies anti-IgA.

          -  Renal impairment (i.e., serum creatinine exceeds more than 1.5 time the upper limit of
             normal (ULN).

          -  Subjects with aspartate aminotransferase or alanine aminotransferase levels exceeding
             more than 2.5 times the ULN.

          -  Hemoglobin levels &lt;10 mg/dL, platelets levels &lt;100,000/mm3, white blood cells count
             &lt;3.0 k/µL and ESR &gt;50 mm/h or twice above normal.

          -  Known seropositive to Hepatitis C virus, Human immunodeficiency virus-1 and/or -2.

          -  Subjects with a history of intolerance to fructose.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marinos Dalakas</last_name>
    <role>Principal Investigator</role>
    <affiliation>Coordinating Investigator</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sandra Camprubi</last_name>
    <email>sandra.camprubi@grifols.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Karen Rucker</last_name>
    <email>karen.rucker@grifols.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of California</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aaron Fisher</last_name>
      <phone>310-206-8153</phone>
      <email>ADFisher@mednet.ucla.edu</email>
    </contact>
    <investigator>
      <last_name>Susan Perlman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Washington University</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>SUNY Upstate Medical University</name>
      <address>
        <city>Syracuse</city>
        <state>New York</state>
        <zip>13210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alisha Hartwell</last_name>
      <phone>315-464-9756</phone>
      <email>hartweal@upstate.edu</email>
    </contact>
    <investigator>
      <last_name>Burke Jubelt, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Thomas Jefferson University Hospital</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lauren E Fedor</last_name>
      <phone>215-955-4663</phone>
      <email>Lauren.Fedor@jefferson.edu</email>
    </contact>
    <investigator>
      <last_name>Marinos Dalakas</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Montreal Neurological Institute, McGill University</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3A 2B4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Claire Magnussen, PhD</last_name>
      <phone>5143983729</phone>
      <email>claire.magnussen@mcgill.ca</email>
    </contact>
    <investigator>
      <last_name>Daria Trojan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Aarhus Universitets Hospital</name>
      <address>
        <city>Aarhus C</city>
        <zip>8000</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Charlotte G Odgaard</last_name>
      <email>charodga@rm.dk</email>
    </contact>
    <investigator>
      <last_name>Henning Andersen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rigshospitalet</name>
      <address>
        <city>København Ø</city>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anette Anberg</last_name>
      <email>anette.eva.anberg@regionh.dk</email>
    </contact>
    <investigator>
      <last_name>Johannes Klitgaard Jakobsen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Charité Campus Mitte</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Agata Mossakowski, MD</last_name>
      <phone>+49 30 450560116</phone>
      <email>agata-anna.mossakowski@charite.de</email>
    </contact>
    <investigator>
      <last_name>Katrin Hahn, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hannover Medical School</name>
      <address>
        <city>Hannover</city>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chantal Fischer</last_name>
      <phone>'+49 (0) 511 532-8333</phone>
      <email>fischer.chantal@mh-hannover.de</email>
    </contact>
    <investigator>
      <last_name>Susanne Petri, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Jena</name>
      <address>
        <city>Jena</city>
        <zip>07747</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julian Grosskreutz, MD</last_name>
      <phone>0049 3641 9323488</phone>
      <email>julian.grosskreutz@med.uni-jena.de</email>
    </contact>
    <investigator>
      <last_name>Julian Grosskreutz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Westfälische Wilhelms-Universität Münster</name>
      <address>
        <city>Münster</city>
        <zip>48129</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matthias Boentert</last_name>
      <phone>+49 251 8344403</phone>
      <email>matthias.boentert@ukmuenster.de</email>
    </contact>
    <investigator>
      <last_name>Peter Young, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera di Verona-Policlinico G.B. Rossi</name>
      <address>
        <city>Verona</city>
        <zip>37134</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria C Tozzi</last_name>
      <email>mariachiara.tozzi@ospedaleuniverona.it</email>
    </contact>
    <investigator>
      <last_name>Laura Bertolasi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Academisch Medisch Centrum</name>
      <address>
        <city>Amsterdam</city>
        <zip>1105 AZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eric Voorn, PhD</last_name>
      <email>e.l.voorn@amc.uva.nl</email>
    </contact>
    <contact_backup>
      <last_name>Tamar Gibson</last_name>
      <phone>+31 205667692</phone>
      <email>j.t.gibson@amc.uva.nl</email>
    </contact_backup>
    <investigator>
      <last_name>Frans Nollet, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Samodzielny Publiczny Zakład Opieki Zdrowotnej Szpital Uniwersytecki w Krakowie</name>
      <address>
        <city>Krakow</city>
        <zip>31-503</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jan Banach</last_name>
      <phone>0048 12 424 86 00</phone>
      <email>j.t.banach@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Marta Banach, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Samodzielny Publiczny Szpital Kliniczny Nr 4 w Lublinie</name>
      <address>
        <city>Lublin</city>
        <zip>20-954</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Urszula Chyrchel</last_name>
      <phone>+48817244720</phone>
      <email>ullach@poczta.onet.pl</email>
    </contact>
    <investigator>
      <last_name>Konrad Rejdak, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Jaroslaw Wronka</name>
      <address>
        <city>Poznan</city>
        <zip>61-485</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jaroslaw Wronka, MD</last_name>
      <email>jaroslaw.wronka@cr-center.pl</email>
    </contact>
    <investigator>
      <last_name>Jaroslaw Wronka, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Samodzielny Publiczny Centralny Szpital Kliniczny</name>
      <address>
        <city>Warsaw</city>
        <zip>02-097</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Malgorzata Gawel</last_name>
      <phone>'48 22 599 28 58</phone>
      <email>mgawel@wum.edu.pl</email>
    </contact>
    <investigator>
      <last_name>Anna Kaminska, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Spitalul Clinic Colentina</name>
      <address>
        <city>Bucharest</city>
        <zip>020125</zip>
        <country>Romania</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Institut Guttman Cami Can Ruti</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria del Pilar Sainz</last_name>
      <email>mpsainz@guttmann.com</email>
    </contact>
    <investigator>
      <last_name>Enric Portell</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Danderyds Sjukhus AB</name>
      <address>
        <city>Stockholm</city>
        <zip>18288</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kristian Borg, MD</last_name>
      <phone>+4686555257</phone>
      <email>kristian.borg@sll.se</email>
    </contact>
    <investigator>
      <last_name>Kristian Borg, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Denmark</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Poland</country>
    <country>Romania</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 25, 2014</study_first_submitted>
  <study_first_submitted_qc>June 25, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 27, 2014</study_first_posted>
  <last_update_submitted>January 15, 2018</last_update_submitted>
  <last_update_submitted_qc>January 15, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 17, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>FORCE</keyword>
  <keyword>post-polio syndrome</keyword>
  <keyword>Flebogamma</keyword>
  <keyword>Immune Globulin Intravenous</keyword>
  <keyword>IGIV</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Poliomyelitis</mesh_term>
    <mesh_term>Postpoliomyelitis Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Immunoglobulins</mesh_term>
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>gamma-Globulins</mesh_term>
    <mesh_term>Immunoglobulins, Intravenous</mesh_term>
    <mesh_term>Rho(D) Immune Globulin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

